 Arturo Barbachano-Guerrero
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dengue Virus | 7 | 2026 | 60 | 1.380 |
Why?
| | Dengue | 6 | 2026 | 91 | 1.340 |
Why?
| | Dog Diseases | 2 | 2023 | 106 | 0.860 |
Why?
| | Influenza in Birds | 1 | 2023 | 5 | 0.780 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2023 | 50 | 0.750 |
Why?
| | Viral Nonstructural Proteins | 1 | 2020 | 63 | 0.600 |
Why?
| | Capillary Permeability | 1 | 2020 | 132 | 0.590 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 264 | 0.570 |
Why?
| | Bird Diseases | 1 | 2018 | 16 | 0.560 |
Why?
| | West Nile virus | 1 | 2018 | 41 | 0.550 |
Why?
| | West Nile Fever | 1 | 2018 | 57 | 0.540 |
Why?
| | Endothelial Cells | 1 | 2020 | 877 | 0.400 |
Why?
| | Saliva | 3 | 2026 | 249 | 0.390 |
Why?
| | Carrier State | 2 | 2021 | 78 | 0.320 |
Why?
| | Birds | 2 | 2023 | 86 | 0.320 |
Why?
| | RNA, Viral | 3 | 2026 | 692 | 0.320 |
Why?
| | Sarcoma, Kaposi | 3 | 2021 | 83 | 0.310 |
Why?
| | Mammals | 2 | 2023 | 286 | 0.280 |
Why?
| | HIV-1 | 2 | 2026 | 908 | 0.280 |
Why?
| | CD4 Antigens | 2 | 2026 | 137 | 0.270 |
Why?
| | Pan troglodytes | 2 | 2025 | 62 | 0.270 |
Why?
| | Mexico | 5 | 2020 | 233 | 0.260 |
Why?
| | Chikungunya Fever | 2 | 2018 | 82 | 0.260 |
Why?
| | Herpesvirus 8, Human | 2 | 2018 | 67 | 0.250 |
Why?
| | Aotidae | 1 | 2026 | 10 | 0.240 |
Why?
| | Receptors, CXCR4 | 1 | 2026 | 91 | 0.230 |
Why?
| | Reverse Genetics | 1 | 2025 | 7 | 0.230 |
Why?
| | Gorilla gorilla | 1 | 2025 | 17 | 0.220 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2024 | 35 | 0.210 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2025 | 93 | 0.210 |
Why?
| | Dogs | 2 | 2023 | 478 | 0.210 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2025 | 92 | 0.210 |
Why?
| | DNA Transposable Elements | 1 | 2024 | 124 | 0.200 |
Why?
| | Virology | 1 | 2024 | 36 | 0.200 |
Why?
| | Orthomyxoviridae | 1 | 2024 | 40 | 0.200 |
Why?
| | Alouatta | 2 | 2020 | 3 | 0.200 |
Why?
| | Exons | 1 | 2024 | 364 | 0.200 |
Why?
| | Hemorrhagic Fevers, Viral | 1 | 2022 | 16 | 0.190 |
Why?
| | Arterivirus | 1 | 2022 | 18 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2024 | 248 | 0.180 |
Why?
| | Orthomyxoviridae Infections | 1 | 2023 | 71 | 0.180 |
Why?
| | Influenza A virus | 1 | 2023 | 119 | 0.180 |
Why?
| | Coccidiosis | 1 | 2021 | 1 | 0.180 |
Why?
| | Eucoccidiida | 1 | 2021 | 1 | 0.180 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2020 | 104 | 0.170 |
Why?
| | Animals | 13 | 2026 | 38100 | 0.170 |
Why?
| | Virus Replication | 4 | 2026 | 521 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 273 | 0.160 |
Why?
| | Animals, Domestic | 1 | 2020 | 17 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 185 | 0.150 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.150 |
Why?
| | Signal Transduction | 2 | 2024 | 5223 | 0.140 |
Why?
| | Cell Line | 2 | 2025 | 2823 | 0.140 |
Why?
| | Models, Biological | 2 | 2024 | 1764 | 0.140 |
Why?
| | Chagas Disease | 1 | 2018 | 42 | 0.140 |
Why?
| | Parasite Egg Count | 1 | 2017 | 5 | 0.130 |
Why?
| | Parasite Load | 1 | 2017 | 10 | 0.130 |
Why?
| | Intestinal Diseases, Parasitic | 1 | 2017 | 12 | 0.130 |
Why?
| | HIV Infections | 2 | 2026 | 3195 | 0.130 |
Why?
| | Antigens, Viral | 1 | 2018 | 182 | 0.130 |
Why?
| | Pharynx | 1 | 2018 | 59 | 0.130 |
Why?
| | Phylogeny | 2 | 2018 | 917 | 0.130 |
Why?
| | Nasal Cavity | 1 | 2018 | 61 | 0.130 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 1 | 2017 | 6 | 0.130 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2017 | 5 | 0.130 |
Why?
| | Herpesviridae Infections | 1 | 2018 | 148 | 0.130 |
Why?
| | Mast Cells | 1 | 2018 | 148 | 0.120 |
Why?
| | Zika Virus Infection | 1 | 2018 | 172 | 0.120 |
Why?
| | Escherichia coli | 1 | 2020 | 835 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1507 | 0.120 |
Why?
| | Viruses | 1 | 2018 | 166 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 204 | 0.110 |
Why?
| | Viral Tropism | 2 | 2026 | 36 | 0.110 |
Why?
| | Virus Activation | 1 | 2015 | 94 | 0.110 |
Why?
| | Feces | 1 | 2017 | 496 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 206 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1857 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2020 | 956 | 0.100 |
Why?
| | Bacteria | 1 | 2018 | 766 | 0.090 |
Why?
| | Repressor Proteins | 1 | 2015 | 429 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 636 | 0.090 |
Why?
| | Culicidae | 2 | 2025 | 33 | 0.090 |
Why?
| | Humans | 17 | 2026 | 145750 | 0.090 |
Why?
| | Ecuador | 2 | 2018 | 14 | 0.070 |
Why?
| | Specimen Handling | 2 | 2021 | 183 | 0.070 |
Why?
| | Chikungunya virus | 2 | 2018 | 81 | 0.060 |
Why?
| | Immunocompetence | 1 | 2026 | 46 | 0.060 |
Why?
| | Asthma | 1 | 2018 | 1797 | 0.060 |
Why?
| | Viremia | 1 | 2026 | 160 | 0.050 |
Why?
| | Aedes | 1 | 2025 | 66 | 0.050 |
Why?
| | Genome, Viral | 1 | 2025 | 214 | 0.050 |
Why?
| | Interferons | 1 | 2024 | 186 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 399 | 0.050 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2024 | 108 | 0.050 |
Why?
| | Macaca | 1 | 2022 | 66 | 0.050 |
Why?
| | Virus Internalization | 1 | 2022 | 65 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2024 | 741 | 0.040 |
Why?
| | Primates | 1 | 2022 | 133 | 0.040 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2021 | 21 | 0.040 |
Why?
| | RNA, Protozoan | 1 | 2021 | 60 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 50 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 39 | 0.040 |
Why?
| | Asymptomatic Infections | 1 | 2021 | 37 | 0.040 |
Why?
| | Monocytes | 1 | 2024 | 539 | 0.040 |
Why?
| | Male | 7 | 2026 | 72992 | 0.040 |
Why?
| | Rainforest | 1 | 2020 | 7 | 0.040 |
Why?
| | Gene Flow | 1 | 2021 | 87 | 0.040 |
Why?
| | Uganda | 1 | 2021 | 90 | 0.040 |
Why?
| | Interleukin-33 | 1 | 2021 | 45 | 0.040 |
Why?
| | Virion | 1 | 2021 | 108 | 0.040 |
Why?
| | Adult | 5 | 2026 | 40867 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 104 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 2021 | 280 | 0.040 |
Why?
| | Female | 7 | 2026 | 79025 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2018 | 17322 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1165 | 0.040 |
Why?
| | Biomarkers | 2 | 2024 | 4302 | 0.040 |
Why?
| | Haplotypes | 1 | 2021 | 500 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2460 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 526 | 0.040 |
Why?
| | Methylhistamines | 1 | 2018 | 1 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 835 | 0.040 |
Why?
| | Tryptases | 1 | 2018 | 12 | 0.030 |
Why?
| | Universities | 1 | 2021 | 445 | 0.030 |
Why?
| | Trypanosoma cruzi | 1 | 2018 | 39 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2967 | 0.030 |
Why?
| | Fibroblasts | 1 | 2024 | 1027 | 0.030 |
Why?
| | Zinc Sulfate | 1 | 2017 | 8 | 0.030 |
Why?
| | Nematoda | 1 | 2017 | 12 | 0.030 |
Why?
| | Formaldehyde | 1 | 2017 | 65 | 0.030 |
Why?
| | Cities | 1 | 2018 | 139 | 0.030 |
Why?
| | Child, Hospitalized | 1 | 2018 | 54 | 0.030 |
Why?
| | Disease Vectors | 1 | 2017 | 15 | 0.030 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.030 |
Why?
| | Sucrose | 1 | 2017 | 114 | 0.030 |
Why?
| | Metagenome | 1 | 2018 | 126 | 0.030 |
Why?
| | Zika Virus | 1 | 2018 | 136 | 0.030 |
Why?
| | Trematode Infections | 1 | 2017 | 49 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 337 | 0.030 |
Why?
| | Insect Vectors | 1 | 2017 | 39 | 0.030 |
Why?
| | Coinfection | 1 | 2018 | 143 | 0.030 |
Why?
| | Whole Genome Sequencing | 1 | 2018 | 178 | 0.030 |
Why?
| | Zoonoses | 1 | 2017 | 39 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1777 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2018 | 344 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 979 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 849 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 2000 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2024 | 2051 | 0.030 |
Why?
| | Horses | 1 | 2017 | 226 | 0.030 |
Why?
| | Tyrphostins | 1 | 2015 | 18 | 0.030 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2015 | 15 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 538 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2026 | 4569 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 93 | 0.030 |
Why?
| | Virus Latency | 1 | 2015 | 90 | 0.030 |
Why?
| | Urban Renewal | 1 | 2014 | 5 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 484 | 0.030 |
Why?
| | Molecular Typing | 1 | 2014 | 21 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1723 | 0.030 |
Why?
| | Aged | 3 | 2018 | 26212 | 0.020 |
Why?
| | RNA Interference | 1 | 2015 | 475 | 0.020 |
Why?
| | Infant | 2 | 2018 | 10089 | 0.020 |
Why?
| | Chiroptera | 1 | 2014 | 59 | 0.020 |
Why?
| | Skin | 1 | 2018 | 754 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 638 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2021 | 3634 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2933 | 0.020 |
Why?
| | Child, Preschool | 2 | 2018 | 11866 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1361 | 0.020 |
Why?
| | Spleen | 1 | 2014 | 508 | 0.020 |
Why?
| | Middle Aged | 3 | 2018 | 36297 | 0.020 |
Why?
| | Pyridines | 1 | 2015 | 609 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1043 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4556 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2874 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2069 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5921 | 0.020 |
Why?
| | Adolescent | 2 | 2018 | 22569 | 0.020 |
Why?
| | Child | 2 | 2018 | 22738 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3551 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8346 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 14250 | 0.010 |
Why?
|
|
Barbachano-Guerrero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|